XXII 22nd Century Group Inc.

FDA's Plan to Lower Nicotine in Cigarettes Has Captured the Attention of Regulators and Public Health Experts Around the World

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that, as reported in Bloomberg News, the landmark plan by the United States Food and Drug Administration (FDA) to reduce nicotine in cigarettes to non-addictive levels is prompting authorities in countries outside of the United States to pursue their own nicotine reduction mandates.

The Bloomberg article declares: “After FDA Commissioner Scott Gottlieb suggested mandating drastic cuts in nicotine levels, public-health experts in New Zealand last week published an action plan recommending such reductions within five years. Canada and Finland say they’re looking into regulating amounts of the drug in tobacco products, while officials in the U.K.’s Department of Health have discussed the U.S. proposal with FDA representatives, according to a person familiar with the matter.”

The Bloomberg article further states that the FDA has “massively raised the attention on reduced-nicotine cigarettes for regulators across the world,” according to Clive Bates, a public health consultant.

The Bloomberg article goes on to point out the fears and limitations of “Big Tobacco” when it reports: “Philip Morris International Inc.’s Director of Product Policy, Rolf Lutz, last year estimated it would cost the company $10 billion to $12 billion to extract nicotine from all the cigarettes it sells across the European Union. Lutz said the cost could be minimized by genetically modifying tobacco plants, but this would take about 20 years.”

In contrast, 22nd Century already possesses proven technology to grow tobacco with non-addictive levels of nicotine. The Company has an inventory of Very Low Nicotine tobacco varieties and is currently developing additional, improved Very Low Nicotine tobacco varieties, including non-GMO varieties.

The Bloomberg article concludes with the assertion that the FDA plan could lead to “the most fundamental change the tobacco industry has ever seen,” as stated by Matthew Myers, president of anti-smoking group Campaign for Tobacco-Free Kids.

“These are very exciting times; public health officials around the world are now actively considering mandates of nicotine levels in tobacco cigarettes made possible by 22nd Century,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “As other countries seek to implement their own reduced nicotine standards, 22nd Century stands ready to partner with any countries – or tobacco companies – that have a genuine interest in improving the health of smokers.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary hemp/cannabis strains for important new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

EN
09/08/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

Emerging Growth Research Releases Q3 2025 Update Report on 22nd Centur...

New York, New York--(Newsfile Corp. - November 26, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), highlighting the Company's now cash-rich balance sheet, full debt repayment, settlement of a $9.5 million insurance case, and stabilization of its Contract Manufacturing Operations (CMO). The updated report also reflects management's revised outlook for EBITDA breakeven, now expected in Q3 2026.Key Highlights from the Update Report:22nd Century Group has fully repaid all remaining debt and settled its long-running $9.5...

 PRESS RELEASE

Emerging Growth Research Releases Q2 2025 Update Report on 22nd Centur...

New York, New York--(Newsfile Corp. - August 22, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q2 2025 results. The report reflects ongoing operational restructuring under new management and revised outlook for EBITDA breakeven pushed to Q2 2026 due to slower-than-expected CMO stabilization and VLN® rollout timing.22nd Century Group Q2 2025 Financial Highlights:Q2 2025 revenue of $4.1 million, down 49% year-over-year from $7.9 million in Q2 2024Q2 2025 revenue declined 31% sequentially from...

 PRESS RELEASE

Emerging Growth Research Releases Q1 2025 Update Report on 22nd Centur...

New York, New York--(Newsfile Corp. - May 21, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q1 2025 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.22nd Century Group Q1 2025 Financial Highlights:Q1 2025 revenue of $6.0 million, up 48% from Q4 2024Q1 2025 gross profit improved to $(0.6) million from $(1.3) million in Q4 2024Operating loss narrowed significantly to $(2.6) million from $(4.4...

 PRESS RELEASE

Emerging Growth Research Releases Quarterly Update Report on 22nd Cent...

Sheridan, Wyoming--(Newsfile Corp. - April 10, 2025) - Emerging Growth Research is pleased to release its latest quarterly update on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q4 2024 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.To read the full report, please visit: Q4 2024 Financial Highlights:Revenue was $4.0 million, down 45% YoY, reflecting expected attrition due to CMO contract price hikes. Gross profit improved YoY to $(1.3) million from $(7.8) million. Opera...

 PRESS RELEASE

Emerging Growth Research Releases New Initiation Report on the 22nd Ce...

Sheridan, Wyoming--(Newsfile Corp. - February 19, 2025) - Emerging Growth Research is pleased to announce the release of its new initiation report on the 22nd Century Group, Inc. (NASDAQ: XXII). The Company has made significant strides in its operational and financial restructuring under new management, with only the warrant overhang remaining to be addressed. To read this report, please visit XXII's landing page on the Emerging Growth website, located here: .XXII's new management has successfully reduced operating cash losses in the first nine months of 2024 and further decreased the Company'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch